Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy

Single AAV intravenous dose achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions

Excerpt from the Press Release:

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced the presentation of preclinical data demonstrating a single intravenous (IV) dose of its novel GBA1 gene replacement therapy achieved widespread distribution in the central nervous system (CNS) and peripheral tissues of mice, and substantially raised levels of the GCase enzyme in both in vivo and in vitro models. The results are available in an on-demand poster session throughout the virtual Congress of the European Society of Gene and Cell Therapy (ESGCT) Oct. 19-22.

“These encouraging preclinical results demonstrate that a single IV dose of GBA1 transgenes transported by a blood-brain barrier penetrant AAV capsid can effectively deliver therapeutically relevant levels of GBA1 protein to multiple brain regions of mice. Notably, the increase over endogenous GCase levels in the range of 300% – 660% is promising given increased GCase levels of 30-50 percent is anticipated to be clinically impactful,” said Glenn Pierce, M.D., Ph.D., interim chief scientific officer of Voyager. “These data show the potential that blood-brain barrier penetrant capsids may have to address severe neurological diseases as compared to loco-regional injection of AAV into the CNS and offer a solid foundation for continued investigation of this novel approach.”

Data presented at ESGCT demonstrates that AAV gene transfer of GBA1 transgenes in the cells of mouse models significantly reduced GCase enzyme activity and the accumulation of glycosphingolipids compared to non-AAV delivery. The treatment was well tolerated at all doses and resulted in the safe delivery of therapeutically relevant levels of GBA1 protein to multiple brain regions in mice. Key findings included:

• AAV vector optimized GBA1 achieved widespread distribution and sustained correction of GCase activity after IV administration in WT mice.
• Consistent voltage gated (VG) distribution and GCase activity was observed across the CNS following IV delivery.
• IV administration of BBB-penetrant capsid optimized GBA1 transgenes at a high dose resulted in approximately a 300% – 660% increase over endogenous GCase levels, suggesting the potential for dose reductions given that increased GCase activity of 30% – 50% is anticipated to be clinically impactful.
• Results validate GBA1 transgene-level DRG tissue-detargeting approach in vitro.

Click the button below to read the entire Press Release:

Continue Reading The Press Release